Flag­ship-backed Evelo Bio­sciences joins Covid-19 hunt with pro­pos­al for bac­te­ria tri­al

A Flag­ship-backed biotech wants to fight the mi­crobe now rav­aging much of the earth with an­oth­er mi­crobe.

To­day, Evelo Bio­sciences an­nounced they filed an IND to test their lead drug — a spe­cial­ly-grown bac­te­ria — in Covid-19 pa­tients. The idea is that the bac­te­ria, orig­i­nal­ly de­vel­oped to treat in­flam­ma­to­ry dis­or­ders, will turn down the im­mune sys­tem in pa­tients, po­ten­tial­ly calm­ing the over­ac­tive in­flam­ma­to­ry re­sponse that doc­tors be­lieve is caus­ing the most se­vere symp­toms in at least some pa­tients.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.